These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25713403)

  • 1. What does it mean to be 'amyloid-positive'?
    Fagan AM
    Brain; 2015 Mar; 138(Pt 3):514-6. PubMed ID: 25713403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier.
    Lombardi G; Berti V; Tedde A; Bagnoli S; Piaceri I; Polito C; Lucidi G; Ferrari C; Ginestroni A; Moretti M; Pupi A; Nacmias B; Sorbi S
    J Alzheimers Dis; 2017; 57(3):697-703. PubMed ID: 28304299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
    Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid biomarkers: pushing the limits of early detection.
    Rabinovici GD
    Brain; 2016 Apr; 139(Pt 4):1008-10. PubMed ID: 27012491
    [No Abstract]   [Full Text] [Related]  

  • 7. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease.
    Toledo JB; Bjerke M; Da X; Landau SM; Foster NL; Jagust W; Jack C; Weiner M; Davatzikos C; Shaw LM; Trojanowski JQ;
    JAMA Neurol; 2015 May; 72(5):571-81. PubMed ID: 25822737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Amyloid PET imaging with [18F]AV-45].
    Tateno A; Okubo Y
    Nihon Rinsho; 2011 Oct; 69 Suppl 8():561-4. PubMed ID: 22787851
    [No Abstract]   [Full Text] [Related]  

  • 11. The Centers for Medicare & Medicaid Services and amyloid-β positron emission tomography for Alzheimer disease.
    Steinbrook R
    JAMA Intern Med; 2014 Jan; 174(1):135. PubMed ID: 24081002
    [No Abstract]   [Full Text] [Related]  

  • 12. Tracking brain amyloid-β in presymptomatic Alzheimer's disease.
    Jagust W
    Lancet Neurol; 2012 Dec; 11(12):1018-20. PubMed ID: 23137951
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.
    Lewczuk P; Matzen A; Blennow K; Parnetti L; Molinuevo JL; Eusebi P; Kornhuber J; Morris JC; Fagan AM
    J Alzheimers Dis; 2017; 55(2):813-822. PubMed ID: 27792012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
    Schöll M; Wall A; Thordardottir S; Ferreira D; Bogdanovic N; Långström B; Almkvist O; Graff C; Nordberg A
    Neurology; 2012 Jul; 79(3):229-36. PubMed ID: 22700814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amyloid-β positron emission tomography in the diagnostic evaluation of alzheimer disease: summary of primary findings and conclusions.
    Pearson SD; Ollendorf DA; Colby JA
    JAMA Intern Med; 2014 Jan; 174(1):133-4. PubMed ID: 24081022
    [No Abstract]   [Full Text] [Related]  

  • 16. Florbetapir-PET imaging and postmortem beta-amyloid pathology.
    Carome M; Wolfe S
    JAMA; 2011 May; 305(18):1857; author reply 1857-8. PubMed ID: 21558513
    [No Abstract]   [Full Text] [Related]  

  • 17. From Alois to Amyvid: seeing Alzheimer disease.
    Furst AJ; Kerchner GA
    Neurology; 2012 Oct; 79(16):1628-9. PubMed ID: 22786589
    [No Abstract]   [Full Text] [Related]  

  • 18. [Searched for and found: non-demented patients with Alzheimer's disease].
    Engelborghs S
    Tijdschr Psychiatr; 2011; 53(9):654-6. PubMed ID: 21898323
    [No Abstract]   [Full Text] [Related]  

  • 19. [Amyloid beta peptide].
    Kowa H; Iwatsubo T
    Nihon Rinsho; 2004 Nov; 62 Suppl 11():307-9. PubMed ID: 15628403
    [No Abstract]   [Full Text] [Related]  

  • 20. An imaging agent for amyloid.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):54-5. PubMed ID: 22777304
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.